WaveMan
WaveMan · Company
NKTR · Nektar Therapeutics
> Search tickers & screens ⌘K
LIVE
← All companies

NKTR Nektar Therapeutics (NKTR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000906709
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
174
13F, latest reported quarter

What the filings say about NKTR

Insiders, 180 days
-$2.0M net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$43.5K
2 notices

Nektar Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, NEKTAR THERAPEUTICS insiders sold a net $2.0M of stock across 125 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
ROBIN HOWARD W
President & CEO
SELL
2026-08-20 SECtraded 2026-08-18
418
$30.1K
-49.4%
Context
  • 38 earlier Form 4 trades (code P or S) here by this insider (38 sales), the last on Jun 17, 2026.
  • The trade is 0.8% of the 54,627 shares held after it.
  • 1 other insider sold within 30 days.
  • 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO ROBIN HOWARD W sold about $30.1K of NKTR on Aug 18, 2026; 1 other insider sold within 30 days and 174 funds added in the latest 13F quarter.
Zalevsky Jonathan
Chief R&D Officer
SELL
2026-08-20 SECtraded 2026-08-18
186
$13.4K
-49.4%
Context
  • 30 earlier Form 4 trades (code P or S) here by this insider (30 sales), the last on Jun 30, 2026.
  • The trade is 1.9% of the 9,570 shares held after it.
  • 1 other insider sold within 30 days.
  • 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief R&D Officer Zalevsky Jonathan sold about $13.4K of NKTR on Aug 18, 2026; 1 other insider sold within 30 days and 174 funds added in the latest 13F quarter.
Zalevsky Jonathan
Chief R&D Officer
SELL
2026-07-02 SECtraded 2026-06-30
5,681
$397.7K
-48.8%
Context
  • 29 earlier Form 4 trades (code P or S) here by this insider (29 sales), the last on Jun 15, 2026.
  • The trade is 58.2% of the 9,756 shares held after it.
  • 1 other insider sold within 30 days.
  • 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief R&D Officer Zalevsky Jonathan sold about $397.7K of NKTR on Jun 30, 2026, the largest insider sale at the company since 2021; 1 other insider sold within 30 days and 174 funds added in the latest 13F quarter.
ROBIN HOWARD W
President & CEO
SELL
2026-06-18 SECtraded 2026-06-17
5,500
$334.5K
-43.0%
Context
  • 36 earlier Form 4 trades (code P or S) here by this insider (36 sales), the last on Jun 16, 2026.
  • The trade is 9.2% of the 59,545 shares held after it.
  • 1 other insider sold within 30 days.
  • 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO ROBIN HOWARD W sold about $334.5K of NKTR on Jun 17, 2026; 1 other insider sold within 30 days and 174 funds added in the latest 13F quarter.
ROBIN HOWARD W
President & CEO
SELL
2026-06-18 SECtraded 2026-06-17
4,500
$277.4K
-43.0%
Context
  • 36 earlier Form 4 trades (code P or S) here by this insider (36 sales), the last on Jun 16, 2026.
  • The trade is 8.2% of the 55,045 shares held after it.
  • 1 other insider sold within 30 days.
  • 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO ROBIN HOWARD W sold about $277.4K of NKTR on Jun 17, 2026; 1 other insider sold within 30 days and 174 funds added in the latest 13F quarter.
125 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 120 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$2.0M over 180 days
-$43.5K over 90 days
below 70% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
174 funds bought in last quarter
more than 86% of Pharma & Biotech
Revenue
-43.9% year over year
below 78% of Pharma & Biotech
Margin
-297.1% net margin
below 71% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
24.7% of the float short (float per yahoo 2026-10-27) · 3.5 days to cover · settled 2026-10-15
more than 95% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NKTR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-41.2%12M
-45%-11%+24%+58%2025-102025-122026-022026-042026-062026-082026-10 2026-06-30 · Zalevsky Jonathan sold $397.7K2026-06-15 · Zalevsky Jonathan sold $336.2K2026-06-17 · ROBIN HOWARD W sold $334.5K2026-06-16 · ROBIN HOWARD W sold $318.0K2026-06-16 · ROBIN HOWARD W sold $285.2K2026-06-17 · ROBIN HOWARD W sold $277.4K2026-01-20 · Zalevsky Jonathan sold $137.9K2025-11-25 · ROBIN HOWARD W sold $119.8K2025-11-25 · Zalevsky Jonathan sold $62.8K2025-11-25 · Wilson Mark Andrew sold $34.2K2026-02-18 · ROBIN HOWARD W sold $30.9K2026-08-18 · ROBIN HOWARD W sold $30.1K2026-05-19 · ROBIN HOWARD W sold $29.1K2026-08-18 · Zalevsky Jonathan sold $13.4K2026-02-18 · Zalevsky Jonathan sold $13.1K2026-05-19 · Zalevsky Jonathan sold $13.0K2026-08-18 · ROBIN HOWARD W filed to sell $30.1K2026-08-18 · Zalevsky Jonathan filed to sell $13.4K2026-06-30 · JONATHAN ZALEVSKY filed to sell $371.5K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NKTR: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
5,067,920 sh
$353.8M
Two Seas Capital LP
3,092,234 sh
$215.9M
BlackRock, Inc.
2,941,851 sh
$205.4M
BVF INC/IL
2,391,075 sh
$166.9M
VANGUARD CAPITAL MANAGEMENT LLC
1,496,849 sh
$104.5M

Congress trades in NKTR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NKTR planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
ROBIN HOWARD W
Filed 2026-08-18
$30.1K
Zalevsky Jonathan
Filed 2026-08-18
$13.4K
JONATHAN ZALEVSKY
Filed 2026-06-30
$371.5K

NKTR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
F/m Emerald Life Sciences Innovation ETF
$3.3M position · as of 2026-05-31
3.1%
Global Endurance Portfolio
$392.1K position · as of 2026-06-30
2.4%
F/m Emerald Special Situations ETF
$685.1K position · as of 2026-07-31
2.1%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$8.0M position · as of 2026-06-30
1.9%
PROFUND VP PHARMACEUTICALS
$209.6K position · as of 2026-06-30
1.8%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$292.4K position · as of 2026-07-31
1.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
25 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
9
Phase 1
0 active
5
Phase 2
1 active
5
Phase 3
2 active
6
Multi-phase
0 active
What changed recently
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Ve
2026-09-19 · Active Not Recruiting → Completed
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Howard W. Robin
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$3.1M
-$773.2K
$1.1M
-97%
+19%
2022
$11.3M
-$8.7M
$3.1M
-90%
+14%
2021
$11.2M
$8.0M
$4.4M
-37%
+26%
2020
$11.2M
$6.5M
$4.4M
-21%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.0M sold by insiders over 180 days, 174 funds added last quarter, $43.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NKTR financials

Revenue growth
-43.9%
XBRL, annual
Net margin
-297.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$54.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-287.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$234.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-35.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-24.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-24.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-18.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$55.2M$98.4M$90.1M$92.1M
Operating income-$140.1M-$105.2M-$263.7M-$376.2M
Net income-$164.0M-$119.0M-$276.0M-$368.0M
EPS (diluted)-9.73-8.68-1.45-1.97
Operating cash flow-$208.5M-$175.7M-$192.6M-$304.0M
Cash$15.1M$44.3M$35.3M$88.2M
Buybacks$0$3.0M$0n/a
SEC XBRL, fiscal years, as known on 2026-10-28

NKTR Stock Sonar score 5/7 axes

Find similar shapesCompare

NKTR ranks highest on institutional and government (86th percentile) and profitability (66th), and lowest on insider conviction (14th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
66
Inputs
  • Return on equity-35.7% · 64 pct, sector of 545
  • Return on assets-24.1% · 64 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-24.3% · 70 pct, sector of 576
Growth
22
Inputs
  • Revenue growth, YoY-43.9% · 22 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
14
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.0M · 29 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
86
Inputs
  • Funds adding, latest quarter174 · 86 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
24
Inputs
  • Short interest, % of float+24.6% · 8 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+12.8% · 40 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NKTR filings, in plain words

Are Nektar Therapeutics insiders buying or selling NKTR?

In the 180 days to 2026-10-28, Nektar Therapeutics insiders were net sellers, a net $2.0M across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of NKTR?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $43.5K of stock; the latest, by ROBIN HOWARD W, was filed 2026-08-18.

Read the full summary

In the 180 days to 2026-10-28, Nektar Therapeutics insiders were net sellers of NKTR, a net $2.0M across purchases and sales reported on Form 4 by 2 sellers. None of the 10 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $43.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies